{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:57:52Z","timestamp":1778525872481,"version":"3.51.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Congenital thrombotic thrombocytopenic purpura (cTTP) is a thrombotic microangiopathy (TMA) characterized by severe hereditary ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) deficiency caused by <jats:italic>ADAMTS13<\/jats:italic> mutations. This rare autosomal recessive genetic disorder is often misdiagnosed as immune thrombocytopenia (ITP) or hemolytic uremic syndrome (HUS). Here, we report a 21-year-old male cTTP patient with a compound heterozygous <jats:italic>ADAMTS13<\/jats:italic> mutation. The patient was admitted for acute thrombocytopenia, with a 5-year history of chronic thrombocytopenia and 1\u202fmonth of renal dysfunction. Initially diagnosed with ITP, he was treated with immunosuppressive therapy, including glucocorticoids and intravenous immunoglobulin, which provided temporary relief but failed to prevent recurrent thrombocytopenia. Ultimately, cTTP was confirmed by the low ADAMTS13 0% activity and two heterozygous variants (c.1335del and c.1045C\u202f&amp;gt;\u202fT) in the <jats:italic>ADAMTS13<\/jats:italic> gene, and the patient received prophylactic fresh-frozen plasma (FFP) infusions every 2\u20133\u202fweeks regularly. Interestingly, the patient also exhibited elevated sC5b-9 levels during the acute phase, necessitating differentiation from HUS. This report highlights a cTTP caused by a compound heterozygous <jats:italic>ADAMTS13<\/jats:italic> mutation, although its pathogenesis requires further investigation. Given the atypical clinical manifestations of cTTP, it is necessary to conduct ADAMTS13 activity and even genetic testing in patients with recurrent thrombocytopenia and end-organ damage.<\/jats:p>","DOI":"10.3389\/fmed.2024.1525062","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:17:18Z","timestamp":1736317038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A compound heterozygous ADAMTS13 mutation causes congenital thrombotic thrombocytopenic purpura: a case report"],"prefix":"10.3389","volume":"11","author":[{"given":"Yezi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanting","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duozhuang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"836960","DOI":"10.3389\/fimmu.2022.836960","article-title":"Molecular diagnosis is vital to the accurate classification and Management of Thrombotic Thrombocytopenic Purpura in children","volume":"13","author":"Karsenty","year":"2022","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"151436","DOI":"10.1016\/j.semnephrol.2023.151436","article-title":"HUS and TTP: traversing the disease and the age spectrum","volume":"43","author":"Donadelli","year":"2023","journal-title":"Semin Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jth.12826","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/jcm11113124","article-title":"Vascular occlusion in kidney biopsy is characteristic of clinically manifesting thrombotic Microangiopathy","volume":"11","author":"Kovala","year":"2022","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2018.08.020","article-title":"Complement activation associated with ADAMTS13 deficiency may contribute to the characteristic glomerular manifestations in Upshaw-Schulman syndrome","volume":"170","author":"Itami","year":"2018","journal-title":"Thromb Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12920-021-01099-3","article-title":"An ADAMTS13 mutation that causes hereditary thrombotic thrombocytopenic purpura: a case report and literature review","volume":"14","author":"Li","year":"2021","journal-title":"BMC Med Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3760\/cma.j.issn.0578-1310.2019.01.012","article-title":"Analysis of 5 children with congenital thrombotic thrombocytopenic purpura","volume":"57","author":"Fu","year":"2019","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1055\/s-0038-1637749","article-title":"Genetic and functional characterization of ADAMTS13 variants in a patient cohort with Upshaw-Schulman syndrome investigated in Germany","volume":"118","author":"Hassenpflug","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e0232637","DOI":"10.1371\/journal.pone.0232637","article-title":"Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation","volume":"15","author":"Letzer","year":"2020","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/biomedicines12030621","article-title":"Pathological mechanisms and novel testing methods in thrombotic thrombocytopenic Purpura","volume":"12","author":"Dolin","year":"2024","journal-title":"Biomedicines"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/bloodadvances.2019000601","article-title":"Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome","volume":"3","author":"Fujimura","year":"2019","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.dsx.2021.04.011","article-title":"Alterations in the lipid profile associate with a dysregulated inflammatory, prothrombotic, anti-fibrinolytic state and development of severe acute kidney injury in coronavirus disease 2019 (COVID-19): a study from Cincinnati, USA","volume":"15","author":"Henry","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","article-title":"Interaction between multimeric von Willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis","volume":"199","author":"Bettoni","year":"2017","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2022018644","article-title":"Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura","volume":"141","author":"Cugno","year":"2023","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1053\/j.ajkd.2015.06.032","article-title":"Treatment of congenital thrombotic thrombocytopenic Purpura with Eculizumab","volume":"66","author":"Pecoraro","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1525062\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:17:21Z","timestamp":1736317041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1525062\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":19,"alternative-id":["10.3389\/fmed.2024.1525062"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1525062","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1525062"}}